Determination of Regulatory Review Period for Purposes of Patent Extension; AURORA EV-ICD
Published Date: 2/6/2026
Notice
Summary
The FDA has officially set the review period for the AURORA EV-ICD, a medical device, so its patent can be extended. This means the company behind the device could get extra time to protect their invention, which might affect when generic versions can enter the market. Anyone interested has until February 6, 2026, to share their thoughts with the FDA.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FDA Sets 1,521-Day Review Period
The FDA determined the regulatory review period for the AURORA EV-ICD is 1,521 days total (1,086 days in the testing phase and 435 days in the approval phase). That determination enables the patent owner to seek a patent-term extension (the applicant seeks either 297 or 868 days), which could affect when competing or generic versions can enter the market. The FDA is accepting comments on this determination through February 6, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2026-02382, Collated Steel Staples From the People's Republic of China: Continuation of Antidumping Duty Order and Countervailing Duty Order
The U.S. is keeping extra taxes on steel staples from China because stopping them could hurt American businesses. These rules started in 2020 and will continue from January 30, 2026, to stop unfair pricing and unfair government help. If you import or sell these staples, expect the same duties to stay in place for now.
Next: 2026-02384, Determination of Regulatory Review Period for Purposes of Patent Extension; ALFAPUMP
The FDA has officially set the review period for the ALFAPUMP medical device, which helps the company apply for extra patent time. This means the device’s makers could get more time to protect their invention, potentially boosting their business. Anyone interested has until April 7, 2026, to share their thoughts with the FDA before the decision is final.